What is Milestone Pharmaceuticals Inc Annual Net Profit?

Milestone Pharmaceuticals Inc Annual Net Profit rose 30.44% in the last year to $41.52 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Milestone Pharmaceuticals Inc Price to Earning Ratio?

Milestone Pharmaceuticals Inc Price to Earning Ratio is -2.63, which is negative.

What is Milestone Pharmaceuticals Inc Stock Price?

Milestone Pharmaceuticals Inc Stock Price rose 17.82% and outperformed its sector by 7.92% in the past year.

What is Milestone Pharmaceuticals Inc Quarterly Net profit?

Milestone Pharmaceuticals Inc Quarterly Net profit rose 9.17% YoY to $12.36 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is Milestone Pharmaceuticals Inc Mutual Fund Holding?

Milestone Pharmaceuticals Inc Mutual Fund Holding increased by 0.38% in the last quarter to 2.39.

What is Milestone Pharmaceuticals Inc Promoter Share Holding?

Milestone Pharmaceuticals Inc Promoter Share Holding stayed the same in the most recent quarter at 1.75%.

What is Milestone Pharmaceuticals Inc Institutional Holding?

Milestone Pharmaceuticals Inc Institutional Holding decreased by 7.12% in the last quarter to 46.61.

How is the Milestone Pharmaceuticals Inc today?

The Milestone Pharmaceuticals Inc today is trading in the green, up by 7.89% at 2.05.

How has Milestone Pharmaceuticals Inc performed historically?

The Milestone Pharmaceuticals Inc is currently trading up 7.89% on an intraday basis in the past week the index fell -5.53%. The index has been up 15.17% in the past quarter and rose 17.82% in the past year. You can view this in the overview section.

Milestone Pharmaceuticals Inc XNAS: MIST

Milestone Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Name: Milestone Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Milestone Pharmaceuticals Inc
Rating: 1.82216675
Author: Trendlyne DVM scores

Download real time

2.05 0.15 (7.89%)

83.04% Gain from 52W Low

3.5M XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Milestone Pharmaceuticals Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	109.4
PE TTM Negative PE TTM Unavailable in chosen country	-2.6
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.1
Price to Book Below industry Median Unavailable in chosen country	4.6
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	46.6
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-100
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	9.2
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	30.4
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	7.9

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

4.2 / 100

Technically Moderately Bullish

68.7 / 100

1Yr Price target upside is 400%

4 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Milestone Pharmaceuticals Inc Stock Price Analysis

Day Price Range 7.9% 1 Day return Unavailable in chosen country	2 (LTP) 22.2 LowHigh
Week Price Range -5.5% 1 Week return Unavailable in chosen country	2 (LTP) 1.92.5 LowHigh
Month Price Range 0.5% 1 Month return Unavailable in chosen country	2 (LTP) 1.52.5 LowHigh
52 Week Price Range 17.8% 1 Year return Unavailable in chosen country	2 (LTP) 1.12.5 LowHigh

View full Share Price History

Milestone Pharmaceuticals Inc Live Price Chart

Switch to TradingView

Forecaster - Analyst Share Price Target and Estimates

Inline

Milestone Pharmaceuticals Inc's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-1

Avg. Estimate

-1

Low Estimate

-1.4

High Estimate

-0.5

Current EPS

Avg. Estimate

Consensus Recommendation

4 ANALYST Recommendations

BUY

The consensus recommendation from 4 analysts for Milestone Pharmaceuticals Inc is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Milestone Pharmaceuticals Inc Stock Analysis

Milestone Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Milestone Pharmaceuticals Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$41.52 M	30.44%	positive	Annual Net Profit rose 30.44% in the last year to $41.52 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-2.63	-	negative	Price to Earning Ratio is -2.63, which is negative.
Stock Price	$2.05	17.82%	positive	Stock Price rose 17.82% and outperformed its sector by 7.92% in the past year.
Quarterly Net profit	$12.36 M	9.17%	positive	Quarterly Net profit rose 9.17% YoY to $12.36 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Mutual Fund Holding	2.39 %	0.38%	positive	Mutual Fund Holding increased by 0.38% in the last quarter to 2.39.
Promoter Share Holding	1.75 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 1.75%.
Institutional Holding	46.61 %	-7.12%	negative	Institutional Holding decreased by 7.12% in the last quarter to 46.61.

VIEW LESS

Loading data..

Milestone Pharmaceuticals Inc - Company Profile

What does Milestone Pharmaceuticals Inc do?

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals Inc Management structure

All Gross Remunerations are in USD

Mr. Joseph G. Oliveto

Director, President and Chief Executive Officer

2024

Gross Remuneration

Year

Mr. Amit Hasija

Chief Financial Officer, Principal Accounting Officer and Executive Vice President, Corporate Development

2024

Gross Remuneration

2024

Gross Remuneration

Year

Milestone Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

83.04% Gain from 52W Low

Milestone Pharmaceuticals Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Milestone Pharmaceuticals Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Milestone Pharmaceuticals Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Milestone Pharmaceuticals Inc's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

Consensus Recommendation

The consensus recommendation from 4 analysts for Milestone Pharmaceuticals Inc is BUY

Milestone Pharmaceuticals Inc Stock Analysis

Milestone Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 30.44% in the last year to $41.52 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -2.63, which is negative.

Stock Price rose 17.82% and outperformed its sector by 7.92% in the past year.

Quarterly Net profit rose 9.17% YoY to $12.36 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Mutual Fund Holding increased by 0.38% in the last quarter to 2.39.

Promoter Share Holding stayed the same in the most recent quarter at 1.75%.

Institutional Holding decreased by 7.12% in the last quarter to 46.61.

Milestone Pharmaceuticals Inc - Company Profile

What does Milestone Pharmaceuticals Inc do?

Milestone Pharmaceuticals Inc Management structure

Mr. Joseph G. Oliveto

Director, President and Chief Executive Officer

Mr. Amit Hasija

Chief Financial Officer, Principal Accounting Officer and Executive Vice President, Corporate Development

Milestone Pharmaceuticals Inc Board of directors

Mr. Andrew Saik

Independent Director

Ms. Debra K. Liebert

Independent Director

Dr. Richard C. Pasternak, M.D.

Independent Director

Mr. Stuart M. Duty

Independent Director

Mr. Joseph C. Papa

Director

Mr. Joseph G. Oliveto

Director, President and Chief Executive Officer

Milestone Pharmaceuticals Inc FAQ

How is Milestone Pharmaceuticals Inc today?

Milestone Pharmaceuticals Inc today is trading in the green, and is up by 7.89% at 2.05.

How has Milestone Pharmaceuticals Inc performed historically?

Milestone Pharmaceuticals Inc is currently trading up 7.89% on an intraday basis. In the past week the stock fell -5.53%. stock has been up 15.17% in the past quarter and rose 17.82% in the past year. You can view this in the overview section.